INTRODUCTION
The brain has been considered to be an immunologi cally privileged site for many years (7) . This immune privilege was thought to be due to a seclusion from the peripheral immune system by the blood-brain barrier (BBB), a lack of lymphatic drainage of the brain, and a virtually undetectable expression of major histocompati bility complex (MHC) class II molecules within the brain (36) . However, this immune privilege is not abso lute because it has been demonstrated recently that i) activated T lymphocytes can cross the BBB and migrate through the brain (11) ; ii) MHC class II molecules are expressed at low levels in the brain and can be induced by y-interferon (23, 35) ; iii) soluble antigens injected into the cerebrospinal fluid (CSF) can be transported to the cervical lymph nodes and induce antibody production in the periphery (37) ; iv) direct intrathecal antibody pro duction also occurs in some viral infections and in multi ple sclerosis (26, 28, 32) . Furthermore, in support of the above findings, CNS xenografts undergo delayed rejec tion within a few weeks after implantation, with grafts infiltrated by macrophages, activated microglial cells, and T lymphocytes (9, 19, 22) .
Acceptance of xenogeneic grafts can be achieved by systemic immunosuppressive treatment with cyclosporin A or FK-506 (20, 34) . However, systemic immunosup pression may lead to severe deleterious side effects. To circumvent these problems, a cell encapsulation tech nique has been developed as an immunoisolation system (1) . Polymer capsules consist of a permselective mem brane that sequesters the transplanted cells but allows diffusion of small molecules such as nutrients, growth factors, and molecules released by the cells into and out of the polymer envelope. More importantly, provided there are adequate molecular weight cutoffs, larger mol ecules are prevented from crossing the encapsulating membrane.
Amyotrophic lateral sclerosis (ALS) is a neurodegen erative disorder characterized by progressive degenera tion of lower motoneurons in the spinal cord and brain stem and upper motoneurons in the cerebral cortex. This atrophy results in muscle weakness, paralysis, and death within 3-5 years (30) . Most of the ALS cases are spo radic and have an unknown etiology. No efficient treat ment is currently available for this disease. Various ani mal models of motoneuron diseases have been used in order to identify the molecular mechanisms involved in ALS or to evaluate potential therapeutic agents [for a review see (24) ]. In particular, neurotrophic factors such as ciliary neurotrophic factor (CNTF), neurotrophins, and glial cell line-derived neurotrophic factor (GDNF) exert potent neuroprotective effects in motor nerve axo tomy models of ALS (12, 29, 38, 39) . Some of the major difficulties encountered in the use of neurotrophic fac tors for the treatment of neurodegenerative diseases are: 1) their inability to cross the blood-brain barrier (BBB);
2) the instability of some of these factors, necessitating repeated injections of large doses; and 3) systemic side effects with large amounts of factors. An ex vivo gene therapy approach using transplants of cell lines geneti cally engineered to continuously release neurotrophic factors would therefore constitute a useful tool to deliver such therapeutic molecules continuously within the CSF.
Because in the absence of an immunosuppressive treat ment these xenogeneic cell lines would immediately be rejected, they have been encapsulated using a polymer membrane to protect them from the host immune system (2) . The use of this technique has led to the long-term survival of implanted xenogeneic cells and to efficient neuroprotection in several animal models of neurode generative diseases (27, 33, 40) .
We have performed a phase I/II clinical trial in 12 patients suffering from ALS using the intrathecal deliv ery of human CNTF released by a genetically engi neered hamster fibroblast cell line. The biological results of the first six patients have been published previously (3) . Nanogram quantities of CNTF had been detected in the CSF of the first six implanted patients. The implants had allowed to deliver significant doses of neurotrophic factor directly into the CNS over a period of several weeks. In addition, in contrast to side effects that had been associated with the systemic delivery of large doses of CNTF in an earlier study (4) , no limiting ad verse effects had been observed in any of the patients exposed to intrathecal doses of CNTF (3) . The aim of the present study was to evaluate a potential intrathecal immune response against the implanted genetically engi neered cells in these patients and in six additional pa tients. (21) . Patients were evaluated monthly for 5 months before capsule implantation and once a month thereafter during the whole period of the trial.
MATERIALS AND METHODS

ALS Patients
BHK-CNTF Cell Line and CNTF Assay
A pNUT-hCNTF expression vector containing the human CNTF gene under the control of the metallothionein-1 promoter (2) was transfected into baby hamster kidney (BHK) cells using standard calcium phosphate transfection procedures and selected for CNTF expres sion using increasing concentrations of methotrexate.
The transfected cells were cloned and cell line #72 was assayed for CNTF production using an ELISA kit (R & D Systems, Minneapolis, MN) as previously described (3) . A master cell bank and a working cell bank were generated from this clone and grown in PCI (Hycor, Walkersville, MD), a defined medium used to replace fetal calf serum.
Cell Encapsulation and Capsule Implantation
A preassembled, semipermeable 5-cm-long hollow fiber mounted on a silicone catheter was aseptically filled with BHK-CNTF cells (2) . Each capsule was loaded with approximately 1 x 10 5 cells. One CNTFreleasing implant was surgically placed within the lum bar intrathecal space at the L3-L4 or L4-L5 level of 12 patients suffering from ALS as previously described (3) .
Capsules were retrieved after 3 to 4 months. Some of the patients were reimplanted once or twice with new devices (after retrieval of the preceding implant), either as planned in the clinical protocol (first implant) or when the CNTF levels in the CSF were very low (sec ond and third implant) ( Table 1 ). Patients did not receive any immunosuppression during the whole period of the trial.
Evaluation of CNTF Release From the Capsules and CNTF Levels in the CSF
CNTF release per capsule was evaluated immediately before implantation and at explantation using an ELISA kit as previously described (3) . Cerebrospinal fluid (CSF) was collected through a spinal tap at the time of implantation, every 4 to 6 weeks thereafter, and at explantation. CNTF levels were also evaluated using the same ELISA kit.
Capsule Histology
After explantation, each capsule was placed in fixa tive consisting of 90% sublimated formol and 10% ace tic acid for 3 h and then into 70% ethanol before glycol methacrylate processing (Historesin, Leica, Nussloch/ Heidelberg, Germany). Sections (5 pm) were cut on a Supercut 2065 (Leica), mounted on glass slides, and stained with cresyl violet.
Evaluation of a Humoral and Cellular Immune Response
To reveal the presence of intrathecal antibodies, oligoclonal bands of IgG were evaluated monthly and at the time of implantation and explantation in CSF and serum samples using an isoelectric focusing technique (15) . CSF leukocyte counts were also evaluated. The al bumin quotient (CSF/serum albumin) was assessed as an index of BBB integrity (25) . 
Complement-Dependent
Lymphocytic
Markers.
To assess a cellular immune response in the blood of the patients, the levels of ex pression of the lymphocytic markers CD3, CD4, CD8, CD 16, CD 19, and HLA-DRII were evaluated using cytofluorometry (Q-PREP system, DAKO).
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Two-Dimensional Gel Electrophoresis (2D-PAGE)
and Immunoblotting. Cellular proteins were analyzed by 2D-PAGE using previously described methods (13, 14) . Briefly, 40 pg BHK proteins were separated in the first dimension on Immobiline strips by isoelectric focusing using a nonlinear pH gradient from pH 3 to 10 and proteins were revealed either by silver staining (8) or immunoblotted as described above for the Western blots. However, none of the patients showed any fever or weight loss throughout the whole implantation period.
N-Terminal
Monthly neurological assessment throughout the trial did not show any improvement in the overall outcome (3) . Note that this trial was designed to evaluate safety and tolerability, but not biological efficacy, of intrathe cal expression of CNTF.
Implants of genetically engineered cells (a total of 22 capsules) released an average of 1.60+ 1.35 pg CNTF/ capsule/day 3 days prior to implantation (Table 1) . This large variation is due to differences in loading density (10,000 or 75,000 cells/pl) and in time in vitro before implantation (3-9 days). At explantation (duration of the implantation: 11-30 weeks), most of the devices still released up to hundreds of nanograms of CNTF (Table  1) . CNTF levels in the CSF throughout the whole im plantation period are summarized in Table 1 . Histologi cal analysis of the capsules at the time of explantation showed viable BHK cells. The micrograph of a capsule retrieved 15 months after implantation from patient #6 is shown in Figure 1 . All the capsules were well toler ated. None of the patients showed any acute phase re sponse throughout the whole implantation period [also see (3) ].
A potential cellular immune response against the en capsulated BHK cells was evaluated by counting leuko cyte number in the CSF and by analyzing lymphocytic markers in the blood of the patients. Small increases in the presence of CSF leukocytes (plasmocytes and/or granulocytes) were found after several weeks in patients #1, #5, #6, #7, #11, and #12 (Table 1) . Leukocyte counts ranged from 3 to 57 cells/dl. Control levels range be tween 0.2 and 2 cells/dl. CNTF levels in the CSF of these patients were low or absent at the time their CSF leukocyte levels were increased ( Table 1) bands was also observed transiently in the CSF of pa tients #1, #5, and #11 ( Table 1) . None of the CSF sam ples contained antibodies against the human CNTF transgene produced by the transplanted cells (data not shown). Note that no evidence of an immune response against the implanted cells could be found in the serum of any of the patients.
Western blot analysis of cellular proteins from the BHK cells was performed to identify the antigen(s) rec ognized by the antibodies present in the CSF samples of patients #4, #6, and #10. Two major bands at a molecu lar weight of 70 and 180 kDa (P70 and PI 80, respec tively) were revealed with the CSF of patient #10 (Fig.  2) . No bands, or only faint bands, were observed in the CSF of the other patients (data not shown). To further characterize the antigen(s) recognized by the IgG pres ent in the CSF of patient #10, 2D-PAGE of BHK cell proteins followed by immunoblotting in the presence of CSF was performed. A protein (protein X) with a molec ular weight of approximately 70 kDa and an acidic iso electric point was revealed (Fig. 3) . The diffuse pattern of this protein is due to its extensive glycosylation. Pro tein X was subsequently localized by superimposition of the immunoblot image to an acidic protein of approxi-mately 70 kDa present in extracts of BHK cells after separation by 2D-PAGE and revelation by silver stain ing (Fig. 4 ). This protein is probably a peripheral pro tein, because it is found associated with the whole cell fraction, but not the membrane, nor the cytosolic frac tion of the BHK cells (Fig. 2) . No protein with a relative molecular mass close to that of PI80 was immunodetected using 2D-PAGE analysis. This lack of signal may be attributed to adsorption of protein PI80 to the immo bilized pH gradient (IPG), because it is also absent on silver-stained 2D-PAGE gels (Fig. 4) .
To identify protein X, 1 mg of total BHK cellular protein was separated on a preparative 2D-PAGE and transferred to an Immobilon membrane. The region cor responding to protein X was cut out and N-terminally (2) . Despite the fact that the brain is a rela tively immunoprivileged organ (7, 9, 19, 22) , unencapsu lated cells are rejected due to a delayed cellular immune response, with grafts being infiltrated with activated T lymphocytes and microglial cells (9, 22) . The small in creases in CSF leukocyte numbers observed after 17, 37, and 49 weeks in patients #1, #5, and #6, and after a few weeks in patients #11 and #12, may indicate a weak cellular immune response against the implanted cells. This is corroborated by the absence or low levels of CNTF in the CSF at that time, indicating that the cells may have been rejected. However, because of the short age in CSF samples, it was not possible to investigate this question in more detail by using more sensitive methods. No indication of lymphocyte activation was found in any of the blood samples tested because the proportion of cells positive for the lymphocytic markers CD3, CD4, CD16, CD19, and HLA-DR was unchanged.
In addition, the implanted capsules did not induce a sys temic inflammatory reaction because the blood sedimen tation rate was unchanged, and the levels of white blood cells, lymphocytes, neutrotrophils, and C reactive pro- No indication of an acute antibody-mediated immune rejection of the implanted cells was found in any of the implanted patients. This may be due to i) immune protec tion by the polymer membrane, and/or ii) absence in the CSF of the evaluated patients of preformed antibodies against the major xenoantigen Gal-al,3-Gal present on BHK cells (unpublished observation) (10) . In addition, no antibodies against human CNTF have been found in the CSF or serum of any of the patients. This is in contrast to a previous study in which 60% of the patients treated with large systemic doses of recombinant human CNTF had developed circulating anti-CNTF antibodies (4).
A delayed humoral immune response was observed in the CSF of 3 of the 12 patients, as revealed by the presence of oligoclonal IgG bands and positive re sponses in the ELISA, cytotoxicity, and/or dot blot assays (Table 1, Fig. 7 ). This indicates that local in trathecal production of antibodies occurs in these pa tients. However, the humoral response did not have any negative impact on the patients. Oligoclonal IgG bands were also observed transiently in the CSF of three other patients. However, the absence of a positive response in the other tests, as well as the evidence of a concomitant BBB disruption (small increase in the albumin quotient) in these patients, may indicate that these antibodies are not directed against the implanted BHK cells. No hu moral immune response could be detected in the serum of any of the patients.
Identification of the antigen(s) recognized by the an tibodies present in the CSF of patients #4, #6, and #10 revealed that they were directed against bovine fetuin (Figs. 2, 3, 5, and 7) . The PCI medium used for cultur ing the BHK cells and maintaining the encapsulated cells in vitro before implantation contains bovine fetuin ( Figs. 5 and 6) . Thus, the presence of antibodies against bovine fetuin in the CSF of the three patients implanted with encapsulated BHK cells could be due to fetuin i) adsorbed to the surface of the BHK cells, ii) adsorbed to the synthetic polymer membrane, iii) present in the medium surrounding the cells at the time of implanta tion, and being progressively released into the CSF after implantation. The late appearance of these intrathecal antibodies, as well as the apparent absence of antifetuin antibodies in the other patients, may be due to the insuf ficient sensitivity of the assays used in this study. 
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